The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.

@article{Lu2014TheOB,
  title={The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.},
  author={Min Lu and Lijuan Xia and Yan Michael Li and Xiaoli Wang and Ronald A Hoffman},
  journal={Blood},
  year={2014},
  volume={124 5},
  pages={771-9}
}
The Philadelphia chromosomal-negative chronic myeloproliferative neoplasms (MPNs) originate at the level of the hematopoietic stem cell (HSC). The protracted clinical course of the MPNs has limited the use of potentially toxic treatment modalities, which may eliminate the responsible malignant clone. Treatment with low doses of RG7112, an orally available small-molecule inhibitor of p53-MDM2, both alone and combined with pegylated interferon α 2a (Peg-IFNα 2a), significantly decreased MPN… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
5 Citations
40 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 40 references

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a - 2 a

  • JJ Kiladjian, B Cassinat, S Chevret
  • Blood
  • 2013

Similar Papers

Loading similar papers…